Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Corporate Presentation Corporate Fact Sheet

Latest News

IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer

March 25, 2026

IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026

March 24, 2026

IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY

February 5, 2026

Financial Events

Imunon Fourth Quarter 2025 Financial Results

March 31, 2026 at 11:00 AM EDT

H.C. Wainwright 27th Annual Global Investment Conference

September 5, 2025